The FDA on January 27, 2012 approved INLYTA® for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. INLYTA® is a product of Pfizer, Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on January 27, 2012 approved INLYTA® for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. INLYTA® is a product of Pfizer, Inc.
Advertisement